155 related articles for article (PubMed ID: 37170275)
1. Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.
Erlmeier M; Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
BMC Urol; 2023 May; 23(1):90. PubMed ID: 37170275
[TBL] [Abstract][Full Text] [Related]
2. The role of claudin-6 in chromophobe renal cell carcinoma.
Erlmeier F; Zschäbitz S; Mikuteit M; Autenrieth M; Weichert W; Hartmann A; Steffens S
Histol Histopathol; 2023 Apr; 38(4):403-407. PubMed ID: 36128931
[TBL] [Abstract][Full Text] [Related]
3. Trophoblast Cell Surface Antigen 2 (Trop2) in Chromophobe Renal Cell Carcinoma.
Mikuteit M; Steffens S; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Erlmeier F
Oncology; 2022; 100(6):331-336. PubMed ID: 35168242
[TBL] [Abstract][Full Text] [Related]
4. Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma.
Mikuteit M; Zschäbitz S; Erlmeier M; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
Oncology; 2022; 100(10):536-541. PubMed ID: 35760058
[TBL] [Abstract][Full Text] [Related]
5. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations.
Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
Oncology; 2024; 102(6):503-509. PubMed ID: 38043528
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Erlmeier F; Hartmann A; Autenrieth M; Wiedemann M; Ivanyi P; Steffens S; Weichert W
Med Oncol; 2016 Nov; 33(11):120. PubMed ID: 27696122
[TBL] [Abstract][Full Text] [Related]
7. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
8. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
9. PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
Erlmeier F; Weichert W; Autenrieth M; Wiedemann M; Schrader AJ; Hartmann A; Ivanyi P; Steffens S
Med Oncol; 2017 May; 34(5):71. PubMed ID: 28353093
[TBL] [Abstract][Full Text] [Related]
10. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
[TBL] [Abstract][Full Text] [Related]
11. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
[TBL] [Abstract][Full Text] [Related]
12. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
[TBL] [Abstract][Full Text] [Related]
13. HNF-1β as an immunohistochemical marker for distinguishing chromophobe renal cell carcinoma and hybrid oncocytic tumors from renal oncocytoma.
An J; Park CK; Kim M; Joo JW; Cho NH
Virchows Arch; 2021 Mar; 478(3):459-470. PubMed ID: 32816058
[TBL] [Abstract][Full Text] [Related]
14. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
15. c-Met in chromophobe renal cell carcinoma.
Erlmeier F; Ivanyi P; Hartmann A; Autenrieth M; Wiedemann M; Weichert W; Steffens S
Med Oncol; 2017 Feb; 34(2):15. PubMed ID: 28035577
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of c-KIT (CD117) expression in renal cell carcinoma.
Ahmed EA; Youssif ME
J Egypt Natl Canc Inst; 2009 Jun; 21(2):121-32. PubMed ID: 21057563
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
Tanimoto S; Fukumori T; El-Moula G; Shiirevnyamba A; Kinouchi S; Koizumi T; Nakanishi R; Yamamoto Y; Taue R; Yamaguchi K; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Takahashi M; Kanayama HO
J Med Invest; 2008 Feb; 55(1-2):106-11. PubMed ID: 18319552
[TBL] [Abstract][Full Text] [Related]
18. Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis.
Frees S; Kamal MM; Knoechlein L; Bell R; Ziesel C; Neisius A; Thomas C; Brenner W; Jäger W; Thüroff JW; Roos FC
Urology; 2016 Dec; 98():81-87. PubMed ID: 27262395
[TBL] [Abstract][Full Text] [Related]
19. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms.
Petit A; Castillo M; Santos M; Mellado B; Alcover JB; Mallofré C
Am J Surg Pathol; 2004 May; 28(5):676-8. PubMed ID: 15105658
[TBL] [Abstract][Full Text] [Related]
20. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
